Avanos Medical (NYSE:AVNS) had its target price upped by KeyCorp from $66.00 to $75.00 in a research report sent to investors on Wednesday morning. The firm currently has an overweight rating on the stock. KeyCorp also issued estimates for Avanos Medical’s FY2018 earnings at $1.85 EPS.

Avanos Medical opened at $62.74 on Wednesday, according to MarketBeat.com. Avanos Medical has a 1 year low of $40.83 and a 1 year high of $66.22. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.48 and a quick ratio of 2.96. The firm has a market capitalization of $2.99 billion, a PE ratio of 24.57, a PEG ratio of 3.80 and a beta of 1.60.

Avanos Medical Company Profile

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Featured Story: What is the Book Value of a Share?

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.